{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:39:02Z","timestamp":1790631542708,"version":"4.1.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Acute pain remains one of the most prevalent and burdensome clinical challenges requiring pharmacological intervention, yet opioids\u2014with their well-documented risks of respiratory depression, addiction, and overdose\u2014remain a cornerstone of moderate-to-severe pain management in the absence of efficacious alternatives. Suzetrigine (VX-548) is a novel preferential inhibitor of the voltage-gated sodium channel (VGSC) isoform Nav1.8, recently approved by the US Food and Drug Administration for the treatment of moderate-to-severe acute pain. Through specific inhibition of Nav1.8, which is expressed predominantly in nociceptive sensory neurons of the peripheral nervous system, suzetrigine offers a mechanistically targeted approach to reduce pain at the level of the primary afferent, bypassing the central nervous system circuitry involved in opioid-associated adverse effects. In this review, we examine both the scientific foundation and clinical utility of suzetrigine, integrating evidence from molecular and structural biology, electrophysiology, preclinical animal models, and Phase II and III randomized controlled clinical trials. We discuss the unique allosteric mechanism by which suzetrigine selectively inhibits Nav1.8 to suppress nociceptor excitability, and review six trials, five of which show evidence demonstrating significant analgesic efficacy relative to placebo, and a favorable safety profile. We discuss key limitations of the current clinical evidence base including modest, and sometimes nonexistent efficacy, albeit at the tested doses. Overall, suzetrigine may serve as a proof-of-concept for the development of other VGSC isoform-specific modulators as targeted therapeutic intervention for a range of diseases. Moreover, the development of cost-effective alternatives to prescription opioids may have substantial population health benefits. Further study with more varied pain types with longer durations including thoroughly examining sex differences with suzetrigine as a monotherapy (i.e., with no use of \u201crescue\u201d medications) relative to prescription opioids or nonsteroidal anti-inflammatory drugs (NSAIDs) will provide valuable information that could widely benefit acute pain patients and form a scaffolding to bridge the gap between the well-established preclinical foundation and clinical research to enhance the quality of life of those currently living with chronic pain.<\/jats:p>","DOI":"10.3389\/fmed.2026.1897421","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:10:45Z","timestamp":1785323445000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["From ion channel biology to clinical practice: suzetrigine as a precision analgesic"],"prefix":"10.3389","volume":"13","author":[{"given":"Amaya L.","family":"Bravo","sequence":"first","affiliation":[{"name":"Geisinger College of Health Sciences","place":["Scranton, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey I.","family":"Ajala","sequence":"additional","affiliation":[{"name":"Geisinger College of Health Sciences","place":["Scranton, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Ayo","sequence":"additional","affiliation":[{"name":"Geisinger College of Health Sciences","place":["Scranton, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Piper","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Geisinger College of Health Sciences","place":["Scranton, PA, United States"]},{"name":"Center for Pharmacy Innovation and Outcomes, Geisinger","place":["Danville, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Wengert","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Geisinger College of Health Sciences","place":["Scranton, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"eabj8186","DOI":"10.1126\/scitranslmed.abj8186","article-title":"Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors","volume":"14","author":"Tavares-Ferreira","year":"2022","journal-title":"Sci Transl Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.18553\/jmcp.2025.31.7.729","article-title":"The effectiveness and value of suzetrigine for moderate to severe acute pain: a summary from the Institute for Clinical and Economic Review\u2019s Midwest comparative effectiveness public advisory council","volume":"31","author":"Nikitin","year":"2025","journal-title":"JMCP"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","article-title":"Using effect size\u2014or why the P value is not enough","volume":"4","author":"Sullivan","year":"2012","journal-title":"J Grad Med Educ"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrn2148","article-title":"The action potential in mammalian central neurons","volume":"8","author":"Bean","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"ref5","volume-title":"Ion Channels of Excitable Membranes","author":"Hille","year":"2001"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1749-6632.1999.tb11272.x","article-title":"Diversity of mammalian voltage-gated sodium channels","volume":"868","author":"Goldin","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1113\/jphysiol.2011.224204","article-title":"Voltage-gated sodium channels at 60: structure, function and pathophysiology","volume":"590","author":"Catterall","year":"2012","journal-title":"J Physiol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-031-52197-3_4","volume-title":"Ion Channels as Targets in Drug Discovery","author":"Wengert","year":"2024"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.nurt.2009.08.001","article-title":"Sodium Channel blockers for the treatment of neuropathic pain","volume":"6","author":"Bhattacharya","year":"2009","journal-title":"Neurotherapeutics"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-017-0441-0","article-title":"Sodium Channel blockers in the treatment of epilepsy","volume":"31","author":"Brodie","year":"2017","journal-title":"CNS Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.coph.2013.11.014","article-title":"Targeting sodium channels in cardiac arrhythmia","volume":"15","author":"Remme","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac5464","article-title":"Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist","volume":"350","author":"Ahuja","year":"2015","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e2208211119","DOI":"10.1073\/pnas.2208211119","article-title":"Structural basis for high-voltage activation and subtype-specific inhibition of human Nav1.8","volume":"119","author":"Huang","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.cell.2017.06.039","article-title":"Structure of the Nav1.4-\u03b21 complex from electric eel","volume":"170","author":"Yan","year":"2017","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e0152405","DOI":"10.1371\/journal.pone.0152405","article-title":"Subtype-selective small molecule inhibitors reveal a fundamental role for Nav1.7 in nociceptor Electrogenesis, axonal conduction and presynaptic release","volume":"11","author":"Alexandrou","year":"2016","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.72468","article-title":"NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats","volume":"11","author":"Johnson","year":"2022","journal-title":"eLife"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"C783","DOI":"10.1152\/ajpcell.00070.2007","article-title":"The TTX metabolite 4,9-anhydro-TTX is a highly specific blocker of the Nav1.6 voltage-dependent sodium channel","volume":"293","author":"Rosker","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1021\/acschemneuro.3c00757","article-title":"Molecular pharmacology of selective NaV1.6 and dual NaV1.6\/NaV1.2 channel inhibitors that suppress excitatory neuronal activity ex vivo","volume":"15","author":"Goodchild","year":"2024","journal-title":"ACS Chem Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of Suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e2503570122","DOI":"10.1073\/pnas.2503570122","article-title":"Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine","volume":"122","author":"Stewart","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1124\/molpharm.124.000944","article-title":"State-dependent inhibition of Nav1.8 sodium channels by VX-150 and VX-548","volume":"106","author":"Vaelli","year":"2024","journal-title":"Mol Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"10277","DOI":"10.1523\/JNEUROSCI.22-23-10277.2002","article-title":"Roles of Tetrodotoxin (TTX)-sensitive Na+ current, TTX-resistant Na+ current, and Ca2+ current in the action potentials of nociceptive sensory neurons","volume":"22","author":"Blair","year":"2002","journal-title":"J Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/ddc4030032","article-title":"Suzetrigine: a novel non-opioid analgesic for acute pain management\u2014a review","volume":"4","author":"Jones","year":"2025","journal-title":"DDC"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/15360288.2026.2624502","article-title":"The clinical application of suzetrigine","author":"Yuan","year":"2026","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1212\/WNL.0000000000002333","article-title":"Sodium channel Nav1.8","volume":"86","author":"Han","year":"2016","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jpainsymman.2005.01.011","article-title":"Molecular biology of opioid analgesia","volume":"29","author":"Pasternak","year":"2005","journal-title":"J Pain Symptom Manag"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003495-199600525-00004","article-title":"The mechanisms of action of NSAIDs in analgesia","volume":"52","author":"Cashman","year":"1996","journal-title":"Drugs"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S0026-895X(24)13073-8","article-title":"A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels","volume":"54","author":"Kuo","year":"1998","journal-title":"Mol Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1085\/jgp.201611668","article-title":"Mechanism of sodium channel block by local anesthetics, antiarrhythmics, and anticonvulsants","volume":"149","author":"Tikhonov","year":"2017","journal-title":"J Gen Physiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e202413719","DOI":"10.1085\/jgp.202413719","article-title":"Differential state-dependent Nav1.8 inhibition by suzetrigine, LTGO-33, and A-887826","volume":"157","author":"Jo","year":"2025","journal-title":"J Gen Physiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000003931","article-title":"Suzetrigine (VX-548) exhibits activity-dependent effects on human dorsal root ganglion neurons with differential pain etiology","author":"Uhelski","year":"2026","journal-title":"Pain"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"7909","DOI":"10.1523\/JNEUROSCI.21-20-07909.2001","article-title":"Gating properties of Nav1.7 and Nav1.8 peripheral nerve sodium channels","volume":"21","author":"Vijayaragavan","year":"2001","journal-title":"J Neurosci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1523\/JNEUROSCI.0468-18.2018","article-title":"Increased resurgent sodium currents in Nav1.8 contribute to nociceptive sensory neuron Hyperexcitability associated with peripheral neuropathies","volume":"39","author":"Xiao","year":"2019","journal-title":"J Neurosci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13041-025-01253-3","article-title":"Pharmacological inhibition of NaV1.8 by suzetrigine reveals potent analgesic potential without tolerance development in mice","volume":"18","author":"Ali","year":"2025","journal-title":"Mol Brain"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/bdd.2387","article-title":"Gender difference in the pharmacokinetics and metabolism of VX-548 in rats","volume":"45","author":"Yu","year":"2024","journal-title":"Biopharm Drug Dispos"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1097\/ALN.0000000000005460","article-title":"Suzetrigine, a nonopioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV1.8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2147\/JPR.S509144","article-title":"Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a phase 3 single-arm study for surgical or non-surgical acute pain","volume":"18","author":"McCoun","year":"2025","journal-title":"J Pain Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41582-025-01127-1","article-title":"Targeting sodium channels \u2014 challenges for acute pain and the leap to chronic pain","volume":"21","author":"Alsaloum","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e001431","DOI":"10.1136\/bmjmed-2025-001431","article-title":"Between promise and peril: role of suzetrigine as a non-opioid analgesic","volume":"4","author":"Karri","year":"2025","journal-title":"BMJ Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1056\/NEJMe2305480","article-title":"Trials for managing acute pain \u2014 a clinically meaningful small effect size?","volume":"389","author":"Wallace","year":"2023","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1016\/j.clinthera.2019.10.002","article-title":"Perioperative opioid-sparing strategies: utility of conventional NSAIDs in adults","volume":"41","author":"Martinez","year":"2019","journal-title":"Clin Ther"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1213\/ANE.0b013e3182025a8a","article-title":"The effects of Oral ibuprofen and celecoxib in preventing pain, improving recovery outcomes and patient satisfaction after ambulatory surgery","volume":"112","author":"White","year":"2011","journal-title":"Anesth Analg"},{"key":"ref44","first-page":"31","article-title":"Utilization, spending, and price of opioid medications in the US Medicaid programs between 1991 and 2019","volume":"15","author":"Alsultan","year":"2022","journal-title":"Am Health Drug Benefits"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.amepre.2018.01.034","article-title":"Trends in medical use of opioids in the U.S., 2006\u20132016","volume":"54","author":"Piper","year":"2018","journal-title":"Am J Prev Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e759","DOI":"10.1016\/S2214-109X(24)00514-X","article-title":"Reporting summary results in clinical trial registries: updated guidance from WHO","volume":"13","author":"Chan","year":"2025","journal-title":"Lancet Glob Health"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e1396","DOI":"10.1097\/PR9.0000000000001396","article-title":"A real-world database analysis of the prevalence of pain medication use in the United States","volume":"11","author":"Lopez","year":"2026","journal-title":"Pain Rep"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41580-024-00763-7","article-title":"Structural biology and molecular pharmacology of voltage-gated ion channels","volume":"25","author":"Huang","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/ALN.0000000000005822","article-title":"Suzetrigine for the treatment of acute pain: comment","volume":"144","author":"Siddiqui","year":"2026","journal-title":"Anesthesiology"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1161\/CIRCRESAHA.112.274035","article-title":"Functional NaV1.8 channels in Intracardiac neurons","volume":"111","author":"Verkerk","year":"2012","journal-title":"Circ Res"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/17581869.2024.2421749","article-title":"VX-548 in the treatment of acute pain","volume":"14","author":"Hang Kong","year":"2024","journal-title":"Pain Manag"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"112156","DOI":"10.1016\/j.jclinane.2026.112156","article-title":"Safety and efficacy of Suzetrigine (VX-548) for acute moderate to severe pain in adults; a systematic review and meta-analysis","volume":"111","author":"Irfan","year":"2026","journal-title":"J Clin Anesth"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"12912","DOI":"10.1021\/acs.jmedchem.4c00861","article-title":"Discovery of novel pyrimidine-based derivatives as Nav1.2 inhibitors with efficacy in mouse models of epilepsy","volume":"67","author":"He","year":"2024","journal-title":"J Med Chem"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/s41467-022-28808-5","article-title":"Structural basis for modulation of human NaV1.3 by clinical drug and selective antagonist","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2147\/JPR.S388896","article-title":"A review of the therapeutic targeting of SCN9A and Nav1.7 for pain relief in current human clinical trials","volume":"16","author":"Dormer","year":"2023","journal-title":"J Pain Res"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1097\/j.pain.0000000000001227","article-title":"Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy","volume":"159","author":"McDonnell","year":"2018","journal-title":"Pain"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1038\/s41467-023-38942-3","article-title":"Structural mapping of Nav1.7 antagonists","volume":"14","author":"Wu","year":"2023","journal-title":"Nat Commun"},{"key":"ref58","article-title":"Vertex announces results from phase 2 study of suzetrigine for the treatment of painful lumbosacral radiculopathy","year":"2024"},{"key":"ref59","article-title":"Statistical analysis plan (methods): protocol VX21-548-101 \u2014 a phase 2, randomized, dose-ranging, double-blind, placebo-controlled study evaluating the efficacy and safety of VX-548 for acute pain after a bunionectomy","year":"2022"},{"key":"ref60","article-title":"Statistical analysis plan (methods): protocol VX22-548-104 \u2014 a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of VX-548 for acute pain after a bunionectomy","year":""},{"key":"ref61","article-title":"Statistical analysis plan (methods): protocol VX22-548-105 \u2014 a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of VX-548 for acute pain after an abdominoplasty","year":""}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1897421\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:10:47Z","timestamp":1785323447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1897421\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":61,"alternative-id":["10.3389\/fmed.2026.1897421"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1897421","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1897421"}}